Please note that this meeting will take place as an in-person event in Charlotte, North Carolina and will not live-stream content for virtual participation. The meeting content will be recorded and made available as an on-demand program after the conference. Please see the registration page for details.

CME credit is available for in-person attendance for the designated sessions. On-demand presentations are not eligible for CME.

All presentations are scheduled to be live, in-person presentations at the date and time specified below unless noted otherwise. Program in progress.

*-Short talk from proffered abstract

Friday, May 17, 2024

• Welcome and Opening Keynote Address

Saturday, May 18, 2024

• Plenary Session 1: Plenary Session 1: Tumor Subtypes in 2024 and Beyond— Biological Framework and Potential Clinical Impact
• Plenary Session 2:  Liquid Biopsies for Guiding Treatment Decisions
• Plenary Session 3:  Sex, Hormone and Stromal Interactions in Tumor Growth and Progression
• Proffered Talks

Sunday, May 19, 2024

• Plenary Session 4:  Immune Cell Context and Treatment Responses
• Plenary Session 5: Novel Approaches for Managing Non-invasive Disease
• Plenary Session 6: Novel approaches for managing invasive disease

Monday May 20, 2024

• Plenary Session 7: Management and Treatment of Metastatic Disease
• Keynote Address II
• Plenary Session 8: Future of Artificial Intelligence in Bladder Cancer Research and Patient Management

WELCOME AND OPENING KEYNOTE
6:30-6:40 p.m.

• Dan Theodorescu, Cedars-Sinai Medical Center, Los Angeles, California
• Donna E. Hansel, The University of Texas MD Anderson Cancer Center, Houston, Texas
• Tahlita Zuiverloon, Erasmus MC Cancer Institute, Rotterdam, Netherlands
• Lars Dyrskjøt, Department of Molecular Medicine, Aarhus University Hospital, Denmark

Opening Keynote Address
6:40-7:30 P.m.
CME-Eligible

• Introduction of Keynote Speaker
  Dan Theodorescu, Cedars-Sinai Medical Center, Los Angeles, California
• Cellular and molecular underpinnings of field cancerization and progression to invasive carcinoma in bladder cancer  
  Philip A. Beachy, Stanford University, Stanford, California                    

Opening Reception
7:30 -9 p.m.

Continental Breakfast
7-8 a.m.

Plenary Session 1: tumor subtypes in 2024 and beyond – biological framework and potential clinical impact
8-9:30 a.m.
CME-Eligible

Session Chairs: Lars Dyrskjøt, Department of Molecular Medicine, Aarhus University Hospital, Denmark

• Dare to be Different – Understanding Subtypes and Divergence in Urothelial Carcinoma 
  Sara E. Wobker, University of North Carolina Chapel Hill, Charlotte, North Carolina
• Molecular subtypes of NMIBC
  Sia V. Lindskrog, Aarhus University Hospital, Aarhus, Denmark
• Molecular subtypes and clinical benefit from neoadjuvant chemotherapy: A ten-year update 
  David J. McConkey, Johns Hopkins University, Baltimore, Maryland
• Panelists:
  Lars Dyrskjøt, Department of Molecular Medicine, Aarhus University Hospital, Denmark 
  David J. McConkey, Johns Hopkins University, Baltimore, Maryland
  Sara E. Wobker, University of North Carolina Chapel Hill, Charlotte, North Carolina

Break
9:30-10 a.m.

Plenary Session 2: Liquid biopsies for guiding treatment decisions
10 -11:30 a.m.
CME-Eligible

Session Chairs: Philip H. Abbosh, Fox Chase Cancer Center, Philadelphia, Pennsylvania

• Urine based liquid biopsy for the diagnosis, assessment, and staging of bladder cancer
  Philip H. Abbosh, Fox Chase Cancer Center, Philadelphia, Pennsylvania
• Circulating Biomarkers in Bladder Cancer: can we predict relapse
  Peter Kuhn, University of Southern California, Los Angeles, California
• Towards ctDNA-guided treatment of muscle-invasive bladder cancer
  Lars Dyrskjøt, Department of Molecular Medicine, Aarhus University Hospital, Denmark 

Lunch
11:30 a.m. – 1:30 p.m.

Plenary Session 3: Sex, Hormone and stromal interactions in tumor growth and progression
1:30-3 p.m.
CME-Eligible

Session Chairs: Dan Theodorescu, Cedars-Sinai Medical Center, Los Angeles, California

• Y chromosome loss in cancer drives growth by evasion of adaptive immunity 
  Dan Theodorescu, Cedars-Sinai Medical Center, Los Angeles, California
• Donna E. Hansel, The University of Texas MD Anderson Cancer Center, Houston, Texas
• Immunological Basis of Sex Bias and Therapeutic Opportunities in Bladder Cancer
  Zihai Li, Ohio State University, Columbus, Ohio

Break
3-3:15 p.m.

PROFFERED TALKS
3:15- 4 p.M.
CME-Eligible

Session Chair: Donna E. Hansel, The University of Texas MD Anderson Cancer Center, Houston, Texas

• Functional consequences of APOBEC3-induced non-coding hotspot mutations in bladder cancer* 
  Rouf Banday, National Cancer Institute, Rockville, Maryland
• TRIM29 is required for basal bladder cancer invasive progression*
  Alan Kelleher, University of Michigan, Ann Arbor, Michigan
• Sarcomatoid histological variants of canine muscle-invasive bladder cancer: transcription factor activation highlights pathways of epithelial-mesenchymal transformation similar to humans*
  Karin Allenspach, University of Georgia, Athens, Georgia
  

Lightning talks Session I 
4-4:15 p.m.
Not CME-Eligible

Session Chair: Donna E. Hansel, The University of Texas MD Anderson Cancer Center, Houston, Texas

• Exploring the functional consequences of APOBEC3-induced non-coding hotspot mutations in bladder cancer using massively parallel reporter assays and CRISPR-mediated base editing 
  Nathan Merrill, University of Michigan, Ann Arbor, Michigan
• Racial differences in characteristics and outcomes of adjuvant nivolumab for muscle-invasive urothelial carcinoma (MIUC) in the real-world setting 
  Regina Barragan-Carrillo, City of Hope Comprehensive Cancer Center, Duarte, California

Poster Session A / Reception
4:15-6:15 P.M.

Continental Breakfast
7-8 a.m.

Plenary Session 4: Immune cell context and treatment responses
8-10 a.m.
CME-Eligible

• Tumor HLA-E expression and cytomegalovirus infection modulate NK cell activity in human bladder cancer 
  Amir Horowitz, Icahn School of Medicine at Mount Sinai, New York, New York
• Spatial proteomics and transcriptomics reveal an altered immune cell landscape in bladder cancer patients unresponsive to BCG treatment* 
  Trine Strandgaard, Aarhus University Hospital, Arhaus, Denmark 
• Dissecting innate immune mechanisms of resistance to immune checkpoint blockade therapy in bladder cancer
  Nina Bhardwaj, Icahn School of Medicine at Mount Sinai, New York, New York
• T cell receptor repertoire and diversity are prognostic markers in bladder cancer* 
  Nanna Kristjánsdóttir, Aarhus University, Arhaus, Denmark 
• Immunological Basis of Sex Bias and Therapeutic Opportunities in Bladder Cancer
  Tahlita Zuiverloon, Erasmus MC Cancer Institute, Rotterdam, The Netherlands

Break
10-10:30 A.m.

Plenary Session 5: Novel approaches for managing non-invasive disease
10:30-12:30 p.m.
CME-Eligible

Session Chair: Ashish M. Kamat, The University of Texas MD Anderson Cancer Center, Houston, Texas

• The Evolution of Multi-disciplinary Care for Non-Muscle Invasive Bladder Cancer Patients
  Noah M. Hahn, Johns Hopkins University, Baltimore, Maryland
• EG-70 (detalimogene voraplasmid), a novel, non-viral intravesical gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: preclinical characterization and translation into the clinic* 
  James Sullivan, enGene Inc, Boston, Massachusetts
• Conditional Reprogramming Modeling of Bladder Cancer for Clinical Translation  
  Cheryl T. Lee, The Ohio State University, Columbus, Ohio
• Final results from a Phase I trial of intravesical chemoimmunotherapy with gemcitabine and Bacillus Calmette-Guérin (BCG) for patients with BCG-exposed high-grade non-muscle invasive bladder cancer* 
  Syed Alam, Memorial Sloan Kettering Cancer Center, New York, New York
• Setting the stage for trials in NMIBC
  Ashish M. Kamat, The University of Texas MD Anderson Cancer Center, Houston, Texas

Lunch on Own
12:30-2 p.m.

Plenary Session 6: Novel approaches for managing invasive disease
2-4 p.m.
CME-Eligible

Session Chair: Tahlita Zuiverloon, Erasmus MC Cancer Institute, Rotterdam, Netherlands 

• Current state of the art: Bladder-preserving trimodality therapy for muscle-invasive bladder cancer
  Jason A. Efstathiou, Massachusetts General Hospital, Boston, Massachusetts
• Modulating the PPARγ pathway to augment NECTIN4-targeting chimeric antigen receptor (CAR) T cell therapy* 
  Jonathan Chou, University of California San Francisco, San Francisco, California
• Defining the actionable genome
  David B. Solit, Memorial Sloan Kettering Cancer Center, New York, New York
• Optimizing cystectomy outcomes in MIBC: What’s new in 2024? 
  Jeremy Teoh, The Chinese University of Hong Kong, Hong Kong
• Identifying targeted therapies for muscle invasive bladder cancer via STAG2 expression* 
  Sarah Athans, Roswell Park Comprehensive Cancer Center, Buffalo, New York

Lightning Talk Session II 
4- 4:15 p.m.
Not CME-Eligible

Session Chair: Tahlita Zuiverloon, Erasmus MC Cancer Institute, Rotterdam, Netherlands 

• GSTT2 modulates immune activation and impacts response to BCG immunotherapy in bladder cancer 
  Mugdha Patwardhan, National University of Singapore, Singapore, Singapore 
• Novel mesothelin-based CAR T cells targeting MUC16 as an intravesical bladder cancer therapy 
• Parwiz Abrahimi, Weil Cornell Medicine, New York, New York
  

Poster Session B / Reception
4:15-6:15 p.m.
Not CME-Eligible

Continental Breakfast
7-8 a.m.

Plenary Session 7: Management and treatment of metastatic disease
8-9:30 a.m.
CME-Eligible

Session Chair: Nicholas Simon, National Institutes of Health, Bethesda, Maryland

• The evolving role of immune-based treatment strategies in metastatic urothelial cancer 
  Matt Galsky, Icahn School of Medicine at Mount Sinai, New York, New York
• The Interplay between Mutagenesis and Extrachromosomal DNA Shapes Urothelial Cancer Evolution
  Bishoy M. Faltas, Weill Cornell Medicine, New York, New York
• Metastatic bladder cancer: The expanding role of antibody drug conjugates 
  Nicholas Simon, National Institutes of Health, Bethesda, Maryland

Break
9:30-9:45 a.m.

Closing Keynote Address  
9:45-10:30 a.m.
CME-Eligible

• Introduction of Keynote Speaker
  Lars Dyrskjøt, Department of Molecular Medicine, Aarhus University Hospital, Denmark
• Lessons from glioblastoma diversity, heterogeneity, and beginnings
  Luis F. Parada, Memorial Sloan Kettering Cancer Center, New York, New York
  

Plenary Session 8: Future of Artificial Intelligence in bladder cancer research and patient management
11-12:30 p.m.
CME-Eligible

Session Chair: Joshua J. Levy, Cedars Sinai Medical Center, Monterey Park, California

• AI-powered tool for rapid reliable bladder cancer screening and surveillance: multicenter validation efforts 
  Joshua J. Levy, Cedars Sinai Medical Center, Monterey Park, California
• Exploratory analysis of tumor tertiary lymphoid structures using a novel artificial intelligence–based approach in patients with muscle-invasive urothelial carcinoma from the CheckMate 274 trial* 
  Matthew Milowsky, Radboud University, Nijmegen, Netherlands 
• AI-driven Multimodal Computational Pathology
  Faisal Mahmood, Harvard Medical School, Boston, Massachusetts
• Imaging mass cytometry captures patient heterogeneity enabling BCG response stratification in non-muscle invasive bladder cancer* 
  Ali Foroughi Pour, The Jackson Laboratory for Genomic Medicine, Farmington, Connecticut
• AI in bladder cancer pathology and research: What can we expect and what not?
  Markus Eckstein, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany

Closing Remarks
12:30 p.m.